42 results about "St elevation myocardial infarction" patented technology

The invention relates to an acute myocardial infarction marker and an application thereof, and in particular relates to RFX2 and an application of an agonist thereof in preparing a medicine for diagnosis and treatment on acute myocardial infarction. Based on a high-flux sequencing result, the inventor screens out the RFX2 gene; a molecular biology method verifies that RFX2 has low expression in the peripheral blood and the cardiac muscle tissue of the acute myocardial infarction. The invention provides the potential diagnosis and treatment target spot of the acute myocardial infarction, and has great clinical application values.

The present invention relates to systems and methods for preparing and completing surgical and medical procedures. In particular, the invention relates to kits for improving preparation and completion time for a medical or surgical procedure in which the kit includes modularized compartments containing sterilized medical or surgical equipment and wherein the medical or surgical equipment is organized and / or ordered within the kit to generally correspond to the sequence of steps of the medical or surgical procedure. The kit is particularly applicable to recanalization procedures for stroke patients as well as revascularization procedures for acute myocardial infarction patients where a kit enables faster preparation and completion of these procedures.

The invention provides a twelve-lead standard electrocardiogram acute myocardial infarction intelligent determining system based on artificial intelligence. The twelve-lead standard electrocardiogramacute myocardial infarction intelligent determining system comprises a data acquisition system and a cloud platform data storage system. The data acquisition system is in communication connection withthe cloud platform data storage system. The cloud platform data storage system is connected with a data modeling analysis system. The data modeling analysis system is connected with a data display system. The data acquisition system comprises an electrocardiogram acquisition system, an angiography device, a clinical testing observing table, and time between chest ache occurring and electrocardiogram acquiring. The twelve-lead standard electrocardiogram acute myocardial infarction intelligent determining system depends on a big data cloud platform and establishes an artificial intelligence algorithm based on characteristic identification acute myocardial infarction (fixed property, fixed position and fixed time) of the twelve-lead standard electrocardiogram, thereby establishing a whole myocardial infarction automatic determining intelligent system platform, quickly realizing acute myocardial infarction automatic determining, and improving diagnosis efficiency.

The invention provides an application of an miRNA marker for diagnosing acute myocardial infarction, a product using the miRNA marker and a detection method, and relates to the technical field of medical molecular biology. The miR-26a-1, miR-146a or miR-199a-1 can be singly or jointly applied as markers for assisting early diagnosis of myocardial infarction, and the plasma level of the miR-26a-1,miR-146a or miR-199a-1 is obviously increased in the early stage of occurrence of myocardial infarction; and the miRNA in the blood of patients with acute myocardial infarction is released into the blood earlier than intracellular protein markers, so that the detection of the plasma level of the miRNA can be used as a biomarker for assisting early diagnosis of acute myocardial infarction. The three miRNA markers can be used as markers for early diagnosis of heart diseases, and thus the sensitivity and specificity of disease diagnosis are greatly improved.

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.

Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.

A method and system for treating a patient having an acute myocardial infarction. Such system may comprise at least one tank having a pressurized gas contained therein, at least one housing having a shell and being adapted to at least partially surround a body segment of the patient, a hose / valve device for supplying the compressed gas from the tank to the housing; and a control device for controlling the flow of compressed gas from the tank to the housing in accordance with cardiac systole and cardiac diastolic of the patient to vary the pressure in synchronization with the patient's heart function. The system may be arranged within a moving vehicle, such as an ambulance, an airplane, or a ship.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.

The invention discloses a DSG3 gene as a molecular marker for early diagnosis of acute myocardial infarction. By utilization of a gene chip and a QPCR method, the situation is discovered that expressions of the DSG3 gene in blood of normal persons and patients with acute myocardial infarction show significant difference, and whether a subject suffers from acute myocardial infarction can be determined through detection of the expression situation of the DSG3 gene in blood. A kit for diagnosis of acute myocardial infarction is developed according to correlation. Diagnosis of acute myocardial infarction is carried out through detection of expression of the DSG3 by utilization of the kit. The diagnostic kit can be used for early diagnosis of diseases, and has wide application prospects in clinic.